journal article·2024-07-25Open access

Vaginal Ovule Loaded with Bismuth Lipophilic Nanoparticles and Cetylpyridinium Chloride Inhibits Human Cervical Carcinoma and Candida albicans Growth

Claudio Cabral-Romero, Rene Hernández-Delgadillo, Jesús Alejandro Torres-Betancourt, Claudia María García-Cuellar, Yesennia Sánchez-Pérez, Juan Manuel Solis-Soto, Irene Meester, Nayely Pineda-Aguilar, Sergio Eduardo Nakagoshi-Cepeda, Juan Valerio Cauich-Rodríguez, María Argelia Akemi Nakagoshi-Cepeda

Abstract

Bismuth lipophilic nanoparticles (BisBAL NPs) and cetylpyridinium chloride (CPC) are antineoplastic and antimicrobial in vitro. As a next pre-clinical step, a clinically viable dosage form for vaginal application was developed. Compendial pharmacopeial tests (mass uniformity, disintegration, and compressive mechanics) and inductively coupled plasma optical emission spectroscopy were conducted on in-house developed glycerinated gelatin (60:15 v/w) vaginal ovules containing BisBAL NP-CPC. The antimycotic activity of BisBAL NP-CPC vaginal ovules was analyzed using disk diffusion and cell viability XTT assays. The antitumor properties of BisBAL NP-CPC vaginal ovules were assessed by cell viability MTT tests. BisBAL NP-CPC and drug-free vaginal ovules deposited into ex vivo porcine vaginas disaggregated without signs of adverse cytotoxicity within the timespan of clinical efficacy. BisBAL NP-CPC vaginal ovules demonstrated antifungal efficacy comparable to miconazole: C. albicans growth inhibition haloes in diffusion tests were 23 ± 0.968 mm (n = 3) for BisBAL NP-CPC and 20.35 ± 0.899 mm (n = 3) for miconazole. Likewise, BisBAL NP-CPC vaginal ovules reduced HeLa cell growth by 81%, outperforming the clinical reference of 500 μM 5-fluouracil, which induced a 70% growth inhibition. BisBAL NP-CPC incorporated into glycerinated gelatin vaginal ovules constitute an innovative drug delivery system for topical antimycotic and anti-cervical carcinoma treatments.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cervical Cancer and HPV Research · Reproductive System and Pregnancy · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Laboratorio de Biología Molecular, Facultad de Odontología, Universidad Autónoma de Nuevo León (UANL), Monterrey 66455, Nuevo León, Mexico

Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Ciudad de México 14080, Distrito Federal, Mexico

Departamento de Ciencias Básicas, Universidad de Monterrey, San Pedro Garza García 66238, Nuevo León, Mexico

Centro de Investigación en Materiales Avanzados, S.C. (CIMAV), Subsede Monterrey, PIIT, Apodaca 66628, Nuevo León, Mexico

Centro de Investigación Científica de Yucatán, Unidad de Materiales, Mérida 97205, Yucatán, Mexico

Funding

CONACHyT

References (48)

Show source-provided references
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries10.3322/caac.21660 ↗
2. Cervical cancer: Novel treatment strategies offer renewed optimism10.1016/j.prp.2024.155136 ↗
3. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine10.1093/jnci/93.4.284 ↗
4. Human papillomavirus and cervical cancer10.1128/CMR.16.1.1-17.2003 ↗
5. Cancer causes revisited: Human papillomavirus and cervical neoplasia10.1093/jnci/87.11.779 ↗
6. Cancer statistics for the year 2020: An overview10.1002/ijc.33588 ↗
7. Cetina-Pérez, L., Luvián-Morales, J., Delgadillo-González, M., Castro-Eguiluz, D., Galicia-Carmona, T., Rely, K., Vaca González, R., Lugo-Martínez, G., García-Barrientos, N., and Nateras, A. (2024). Sociodemographic characteristics and their association with survival in women with cervical cancer. BMC Cancer, 24.10.1186/s12885-024-11909-3 ↗
8. Survival analysis and associated factors in patients with cervical cancer financed by the Seguro Popular in Mexico
9. Cervical Cancer in Young Women: Do They Have a Worse Prognosis? A Retrospective Cohort Analysis in a Population of Mexico10.1634/theoncologist.2019-0902 ↗
10. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines
11. The effects of interferon on the expression of human papillomavirus oncogenes10.1099/0022-1317-81-3-695 ↗
12. Peptide-Based Nanovaccines in the Treatment of Cervical Cancer: A Review of Recent Advances10.2147/IJN.S269986 ↗
13. Advance in Nanomedicine for Improving Mucosal Penetration and Effective Therapy of Cervical Cancer10.1002/smll.202303772 ↗
14. Bismuth lipophilic nanoparticles (BisBAL NP) inhibit the growth of tumor cells in a mouse melanoma model10.2174/1871520622666220215124434 ↗
15. A review of bismuth-based nanoparticles and their applications in radiosensitising and dose enhancement for cancer radiation therapy10.1049/nbt2.12134 ↗
16. Gomez, C., Hallot, G., Laurent, S., and Port, M. (2021). Medical Applications of Metallic Bismuth Nanoparticles. Pharmaceutics, 13.10.3390/pharmaceutics13111793 ↗
17. Synthesis and characterization of lipophilic bismuth dimercaptopropanol nanoparticles and their effects on oral microorganisms growth and biofilm formation10.1007/s11051-014-2456-5 ↗
18. Antitumor activity of a hydrogel loaded with lipophilic bismuth nanoparticles on cervical, prostate, and colon human cancer cells10.1097/CAD.0000000000000863 ↗
19. Efficacy of cetylpyridinium chloride used as oropharyngeal antiseptic
20. Cetylpyridinium chloride mouth rinses alleviate experimental gingivitis by inhibiting dental plaque maturation10.1038/ijos.2016.18 ↗
21. Glycosylation and raft endocytosis in cancer10.1007/s10555-020-09880-z ↗
22. García-Cuellar, C.M., Hernández-Delgadillo, R., Solis-Soto, J.M., Meester, I., Sánchez-Pérez, Y., Nakagoshi-Cepeda, S.E., Nakagoshi-Cepeda, M.A.A., Chellam, S., and Cabral-Romero, C. (2022). Cetylpyridinium chloride inhibits human breast tumor cells growth in a no-selective way. J. Appl. Biomater. Funct. Mater., 20.10.1177/22808000221092157 ↗
23. García-Cuellar, C.M., Hernández-Delgadillo, R., Torres-Betancourt, J.A., Solis-Soto, J.M., Meester, I., Sánchez-Pérez, Y., Pineda-Aguilar, N., Nakagoshi-Cepeda, S.E., Sánchez-Nájera, R.I., and Nakagoshi-Cepeda, M.A.A. (2023). Cumulative antitumor effect of bismuth lipophilic nanoparticles and cetylpyridinium chloride in inhibiting the growth of lung cancer. J. Appl. Biomater. Funct. Mater., 21.10.1177/22808000231161177 ↗
24. Mucoadhesive 3D printed vaginal ovules to treat endometriosis and fibrotic uterine diseases
25. Study of dissolution profiles and desintegration of capsules containing the dried hydroethanolic extract of Calophyllum brasiliense10.1590/S0102-695X2012005000145 ↗
26. Janeczko, M., and Kochanowicz, E. (2024). Biochanin A Inhibits the Growth and Biofilm of Candida Species. Pharmaceuticals, 17.10.3390/ph17010089 ↗
27. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction10.1046/j.1471-4159.1997.69020581.x ↗
28. Gonçalves, C.A., Pereira-da-Silva, G., Silveira, R., Mayer, P.C.M., Zilly, A., and Lopes-Júnior, L.C. (2024). Safety, Efficacy, and Immunogenicity of Therapeutic Vaccines for Patients with High-Grade Cervical Intraepithelial Neoplasia (CIN 2/3) Associated with Human Papillomavirus: A Systematic Review. Cancers, 16.10.3390/cancers16030672 ↗
29. Human papillomavirus vaccines10.1016/j.jgyn.2007.11.019 ↗
30. Human papilloma virus (HPV) prophylactic vaccination: Challenges for public health and implications for screening10.1016/j.vaccine.2007.01.016 ↗
31. Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k)10.1111/myc.13248 ↗
32. Preparation and characterization of mucoadhesive thermoresponsive systems containing propolis for the treatment of vulvovaginal candidiasis10.1002/jps.23451 ↗
33. Advances and future perspectives in epithelial drug delivery10.1016/j.addr.2022.114293 ↗
34. Women’s experiences, preferences and perceptions regarding vaginal products: Results from a cross-sectional web-based survey in Portugal10.3109/13625187.2014.980501 ↗
35. Women’s preferences and acceptance for different drug delivery routes and products10.1016/j.addr.2022.114133 ↗
36. Rajan, S.S., Chandran, R., and Abrahamse, H. (2024). Overcoming challenges in cancer treatment: Nano-enabled photodynamic therapy as a viable solution. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 16.10.1002/wnan.1942 ↗
37. Biopolymer-based tumor microenvironment-responsive nanomedicine for targeted cancer therapy10.2217/nnm-2023-0302 ↗
38. Khan, H., Shahab, U., Alshammari, A., Alyahyawi, A.R., Akasha, R., Alharazi, T., Ahmad, R., Khanam, A., Habib, S., and Kaur, K. (2024). Nano-therapeutics: The upcoming nanomedicine to treat cancer. IUBMB Life.10.1002/iub.2814 ↗
39. Avgoustakis, K., and Angelopoulou, A. (2024). Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments. Pharmaceutics, 16.10.3390/pharmaceutics16020179 ↗
40. Additive manufacturing in drug delivery: Innovative drug product design and opportunities for industrial application10.1016/j.addr.2021.113990 ↗
41. Mao, X., Calero-Pérez, P., Montpeyó, D., Bruna, J., Yuste, V.J., Candiota, A.P., Lorenzo, J., Novio, F., and Ruiz-Molina, D. (2022). Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy. Nanomaterials, 12.10.3390/nano12071221 ↗
42. Petre, I., Sirbu, D.T., Petrita, R., Toma, A.D., Peta, E., and Dimcevici-Poesina, F. (2023). Real-world study of Cerviron(®) vaginal ovules in the treatment of cervical lesions of various etiologies. Biomed. Rep., 19.10.3892/br.2023.1618 ↗
43. Chitosan-hydroxypropyl methylcellulose tioconazole films: A promising alternative dosage form for the treatment of vaginal candidiasis10.1016/j.ijpharm.2018.12.011 ↗
44. A novel intravaginal delivery system for itraconazole: In vitro and in vivo evaluation10.2174/156720109787846289 ↗
45. Fenticonazole nitrate for treatment of vulvovaginitis: Efficacy, safety, and tolerability of 1-gram ovules, administered as ultra-short 2-day regimen10.1179/joc.2004.16.2.179 ↗
46. Mitofusin-2 Triggers Cervical Carcinoma Cell Hela Apoptosis via Mitochondrial Pathway in Mouse Model10.1159/000488410 ↗
47. Human serum albumin-bound paclitaxel nanoparticle inhibits cervical carcinoma cell proliferation and oxidative damage through CYP3A4 and CYP2C810.1016/j.heliyon.2024.e24460 ↗
48. Investigation of in-vitro Anti-Cancer and Apoptotic Potential of Garlic-Derived Nanovesicles against Prostate and Cervical Cancer Cell Lines10.31557/APJCP.2024.25.2.575 ↗